Matches in SemOpenAlex for { <https://semopenalex.org/work/W2995109521> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W2995109521 endingPage "S789" @default.
- W2995109521 startingPage "S788" @default.
- W2995109521 abstract "Objectives Drug development is increasingly focused on treatments for oncology and rare diseases. This has resulted in rising drug costs with delayed or limited access to these products. This study aimed to compare drug costs for oncology and orphan products with those from other therapeutic areas. Methods Product details from reimbursement submissions to the NCPE were recorded for 2012-2017. The estimated annual/treatment cost per patient and incremental cost effectiveness ratio (ICER) were extracted from the pharmacoeconomic reviews. These indicators for oncology and orphan products (Group A) were compared to all others (Group B) for the study period. The trends for the two groups were also reviewed by contrasting 2012 with 2017. Results 273 reviews were submitted during the study period, excluding repeat submissions, and 103 full health technology assessments (HTA) were commissioned. 108 reviews were for Group A (39.6%) and the majority of HTA’s (62.1%) involved this group. The estimated annual cost per patient for a drug from Group A more than doubled from 2012(€59,500) to 2017(€130,500). A similar increase was apparent for Group B, however, the annual cost for Group A drugs was almost five times higher. This was also reflected in the percentage of Group A drugs (46.3%) with an ICER greater than the Irish Willingness to Pay (WTP) compared to Group B (8.5%). The percentage of Group A drugs which exceeded the threshold increased from 25% to 50% over the study period. Conclusion It is evident from this study that treatments for cancer and rare diseases are considerably more expensive than those from other therapeutic areas. Also, they more frequently require HTA assessment and are increasingly exceeding agreed WTP thresholds. While some countries are addressing these issues, it is necessary to develop health policies at a European level to ensure appropriate access to these medicines." @default.
- W2995109521 created "2019-12-26" @default.
- W2995109521 creator A5008596056 @default.
- W2995109521 creator A5031842368 @default.
- W2995109521 creator A5038488647 @default.
- W2995109521 creator A5040826899 @default.
- W2995109521 creator A5048599692 @default.
- W2995109521 creator A5089030639 @default.
- W2995109521 date "2019-11-01" @default.
- W2995109521 modified "2023-10-16" @default.
- W2995109521 title "PNS164 PHARMACOECONOMIC ASSESSMENT AND DRUG COSTS OF TREATMENTS FOR CANCER AND RARE DISEASES IN IRELAND" @default.
- W2995109521 doi "https://doi.org/10.1016/j.jval.2019.09.2064" @default.
- W2995109521 hasPublicationYear "2019" @default.
- W2995109521 type Work @default.
- W2995109521 sameAs 2995109521 @default.
- W2995109521 citedByCount "1" @default.
- W2995109521 countsByYear W29951095212023 @default.
- W2995109521 crossrefType "journal-article" @default.
- W2995109521 hasAuthorship W2995109521A5008596056 @default.
- W2995109521 hasAuthorship W2995109521A5031842368 @default.
- W2995109521 hasAuthorship W2995109521A5038488647 @default.
- W2995109521 hasAuthorship W2995109521A5040826899 @default.
- W2995109521 hasAuthorship W2995109521A5048599692 @default.
- W2995109521 hasAuthorship W2995109521A5089030639 @default.
- W2995109521 hasBestOaLocation W29951095211 @default.
- W2995109521 hasConcept C126322002 @default.
- W2995109521 hasConcept C160735492 @default.
- W2995109521 hasConcept C162324750 @default.
- W2995109521 hasConcept C177713679 @default.
- W2995109521 hasConcept C2776738588 @default.
- W2995109521 hasConcept C2779703844 @default.
- W2995109521 hasConcept C2780035454 @default.
- W2995109521 hasConcept C50522688 @default.
- W2995109521 hasConcept C512399662 @default.
- W2995109521 hasConcept C60644358 @default.
- W2995109521 hasConcept C71924100 @default.
- W2995109521 hasConcept C75480439 @default.
- W2995109521 hasConcept C86803240 @default.
- W2995109521 hasConcept C98274493 @default.
- W2995109521 hasConceptScore W2995109521C126322002 @default.
- W2995109521 hasConceptScore W2995109521C160735492 @default.
- W2995109521 hasConceptScore W2995109521C162324750 @default.
- W2995109521 hasConceptScore W2995109521C177713679 @default.
- W2995109521 hasConceptScore W2995109521C2776738588 @default.
- W2995109521 hasConceptScore W2995109521C2779703844 @default.
- W2995109521 hasConceptScore W2995109521C2780035454 @default.
- W2995109521 hasConceptScore W2995109521C50522688 @default.
- W2995109521 hasConceptScore W2995109521C512399662 @default.
- W2995109521 hasConceptScore W2995109521C60644358 @default.
- W2995109521 hasConceptScore W2995109521C71924100 @default.
- W2995109521 hasConceptScore W2995109521C75480439 @default.
- W2995109521 hasConceptScore W2995109521C86803240 @default.
- W2995109521 hasConceptScore W2995109521C98274493 @default.
- W2995109521 hasLocation W29951095211 @default.
- W2995109521 hasOpenAccess W2995109521 @default.
- W2995109521 hasPrimaryLocation W29951095211 @default.
- W2995109521 hasRelatedWork W133299513 @default.
- W2995109521 hasRelatedWork W2085325623 @default.
- W2995109521 hasRelatedWork W2113338089 @default.
- W2995109521 hasRelatedWork W2139255537 @default.
- W2995109521 hasRelatedWork W2384994293 @default.
- W2995109521 hasRelatedWork W2520491083 @default.
- W2995109521 hasRelatedWork W2921819767 @default.
- W2995109521 hasRelatedWork W2996617909 @default.
- W2995109521 hasRelatedWork W2997640121 @default.
- W2995109521 hasRelatedWork W3206420890 @default.
- W2995109521 hasVolume "22" @default.
- W2995109521 isParatext "false" @default.
- W2995109521 isRetracted "false" @default.
- W2995109521 magId "2995109521" @default.
- W2995109521 workType "article" @default.